Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

…, E Salort-Campana, E Delmont, AM Grapperon… - The Lancet …, 2021 - thelancet.com
Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients…

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

…, J Pouget, A Verschueren, AM Grapperon… - The Lancet …, 2021 - thelancet.com
Background Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive
disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and …

The utility of motor unit number index: a systematic review

F Fatehi, AM Grapperon, D Fathi, E Delmont… - Neurophysiologie …, 2018 - Elsevier
The need for a valid biomarker for assessing disease progression and for use in clinical
trials on amyotrophic lateral sclerosis (ALS) has stimulated the study of methods that could …

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera

…, T Dubard, A Echaniz-Laguna, AM Grapperon… - Journal of …, 2020 - Springer
Introduction IgG4 antibodies against neurofascin (Nfasc155 and Nfasc140/186), contactin (CNTN1)
and contactin-associated protein (Caspr1) are described in specific subtypes of …

[HTML][HTML] Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS

…, J Boucraut, E Delmont, A Parlanti, AM Grapperon… - Scientific reports, 2021 - nature.com
This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS)
aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L…

Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 …

…, T Dubard, A Echaniz-Laguna, AM Grapperon… - Clinical …, 2020 - Elsevier
Objective Chronic inflammatory demyelinating polyradiculoneuropathies (CIDP) with
antibodies against neurofascin 155 (Nfasc155) or contactin-1 (CNTN1) have distinctive clinical …

Region‐specific impairment of the cervical spinal cord (SC) in amyotrophic lateral sclerosis: a preliminary study using SC templates and quantitative MRI (diffusion …

H Rasoanandrianina, AM Grapperon… - NMR in …, 2017 - Wiley Online Library
In this preliminary study, our objective was to investigate the potential of high‐resolution
anatomical imaging, diffusion tensor imaging (DTI) and conventional/inhomogeneous …

Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre

…, E Campana-Salort, A Verschueren, AM Grapperon… - Revue …, 2022 - Elsevier
Background Growing numbers of indications for intravenous immunoglobulins (IVIg) in
recent years has resulted in an increase in the consumption of these products. A lack of raw …

Quantitative brain sodium MRI depicts corticospinal impairment in amyotrophic lateral sclerosis

AM Grapperon, B Ridley, A Verschueren, A Maarouf… - Radiology, 2019 - pubs.rsna.org
Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that
mainly affects the upper and lower motor neurons. Recent sodium ( 23 Na) MRI studies have …

Guillain‐Barre syndrome subtype diagnosis: a prospective multicentric European study

…, JL Woodard, S Attarian, AM Grapperon… - Muscle & …, 2018 - Wiley Online Library
Introduction: There is uncertainty as to whether the Guillain‐Barré syndrome (GBS) subtypes,
acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal …